Overview

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial

Status:
Recruiting
Trial end date:
2022-08-07
Target enrollment:
Participant gender:
Summary
Early Mild Outpatient infusion Therapy with ExoFloTM for COVID-19 (EMOTE COVID-19) To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles, ExoFlo, as treatment for mild-moderate COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Direct Biologics, LLC